FLORENCE, Italy and CAMBRIDGE, Mass., January 10, 2025 : The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

A meeting at the Middle East North Africa (MENA)-NCCN Regional Coordinating Center presents new and updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®): MENA Editions, and selected topics highlighting cancer advances, challenges, and opportunities in the region.

Tongue cancer (TC) cells can enter a chemo-resistant state by activating pathways related to autophagy and cholesterol synthesis, report researchers from Institute of Science Tokyo. Using a large-scale library of TC organoids they developed, the researchers performed comprehensive comparative analyses of chemo-sensitive and chemo-resistant cells. Their efforts shed light on promising avenues toward new treatments for tongue cancer.